Menopause Acne: Why Breakouts Start in Midlife and What Actually Treats Them

The short answer

Midlife acne does not look like teenage acne, and treating it like teenage acne is the most common mistake. It concentrates on the lower third of the face — jawline, chin, along the mandible, sometimes the upper neck — rather than the forehead and nose. It tends to produce a smaller number of deep, tender, inflammatory papules and nodules that last for weeks, rather than dense fields of blackheads and whiteheads. It often flares in a cyclical pattern while cycles are still happening, and it sits on skin that is thinner, slower to repair its barrier, and far less tolerant of the benzoyl peroxide washes and scrubs that a teenager shrugs off.

The treatments with actual dermatology guideline support are the same core agents used for acne at any age, sequenced differently for midlife skin: topical retinoids as the backbone, benzoyl peroxide to reduce antibiotic resistance and treat inflammatory lesions, topical or oral antibiotics used in short courses and never alone, hormonal therapy — combined oral contraceptives or spironolactone — for the hormonally patterned cases that topicals do not control, and isotretinoin for severe, scarring, or treatment-resistant disease. The American Academy of Dermatology's acne guidelines organize care around exactly this ladder. What follows is how each rung applies specifically to skin in the menopause transition, when PCOS or another cause deserves a workup, and the short list of things that reliably make midlife acne worse.

The hormonal mechanism: a ratio shift, not an androgen surge

Sebaceous glands and the cells lining hair follicles carry androgen receptors. Androgens — mainly testosterone and its more potent tissue conversion product dihydrotestosterone — drive sebum production and influence how follicular cells stick together and shed. Estrogen broadly opposes this at the level of the skin. Through most of adult life the two signals are balanced enough that the follicle behaves.

Perimenopause breaks the balance from the estrogen side. Ovarian estradiol output becomes erratic, with high-amplitude swings before the eventual decline, while ovarian and adrenal androgen production tapers slowly with age rather than stopping. Sex hormone binding globulin, which is partly estrogen-driven, tends to fall — and because it is the protein that keeps most circulating testosterone bound and biologically inert, a drop in it raises free testosterone even when total testosterone is unchanged. Insulin resistance, which becomes more common with midlife weight redistribution, lowers sex hormone binding globulin further.

This is why the standard reassurance — 'your testosterone is normal' — is both true and unhelpful. The adult female acne clinical practice literature describes affected women as typically having androgen levels within the reference range; what has changed is the ratio and the free fraction, and individual follicular sensitivity to androgens varies between women regardless of blood levels. Two women with similar labs can have completely different skin.

The practical consequence is that treatment aimed at the follicle — retinoids, benzoyl peroxide — works on the same biology it always did, while treatment aimed at the hormone signal works by blocking the androgen receptor or lowering free androgen rather than by correcting a deficiency. Neither approach requires an abnormal lab value to be appropriate.

How midlife acne differs from teenage acne

The single most useful clinical observation is where the lesions sit. Adolescent acne favors the T-zone: forehead, nose, upper cheeks, often the upper back and chest, with abundant open and closed comedones — blackheads and whiteheads — as the dominant lesion. Adult female acne, as described in the adult female acne clinical practice literature and on the American Academy of Dermatology's adult acne patient resource, favors the lower third of the face: the chin, the jawline, along the angle of the mandible, sometimes extending onto the upper neck.

The lesion type differs too. Instead of many superficial comedones, midlife acne typically produces a smaller number of deeper, tender, red inflammatory papules and nodules that persist for weeks and often leave a brown or red mark long after the bump has flattened. Women frequently describe them as 'under the skin' and as painful before they are visible. Because there are fewer lesions, the disease is often labeled mild by severity counts while being genuinely disabling in terms of pain, scarring risk and appearance.

The skin they sit on is different as well. Midlife facial skin is thinner, produces less overall sebum outside the affected follicles, repairs its barrier more slowly, and is more prone to post-inflammatory hyperpigmentation that lingers. This is why regimens borrowed from teenage acne — foaming benzoyl peroxide washes twice daily, alcohol toners, gritty scrubs — cause stinging, peeling and redness that force women to quit before any treatment has had a chance to work.

There is also a timing pattern. While cycles continue, flares often cluster in the week before bleeding. As cycles become irregular, that predictability disappears and breakouts feel random, which is itself a clue that the driver is the hormonal transition rather than a new product or food.

What else it could be: the lookalikes that get treated as acne

Not every lower-face breakout in midlife is acne, and the wrong label leads to months of wrong treatment. Papulopustular rosacea is the most frequent impostor: it produces inflammatory papules and pustules on the central face in the same age group, but it comes with background redness, flushing triggered by heat, alcohol or spicy food, visible small vessels, and an absence of comedones. Benzoyl peroxide and strong retinoids often aggravate it.

Perioral dermatitis produces clusters of tiny papules and pustules around the mouth, nose or eyes, characteristically sparing a narrow rim of skin right at the lip border. It is strongly associated with topical steroid use — including inhaled steroids for asthma and steroid creams applied to the face for unrelated reasons — and it typically worsens if treated as acne with occlusive products.

Gram-negative folliculitis and Malassezia folliculitis both mimic acne and both tend to appear in people who have been on long courses of oral antibiotics. Malassezia folliculitis produces uniform, itchy, monomorphic small papules, often on the forehead, chest and back, and it responds to antifungal rather than antibacterial treatment. If acne has been getting steadily worse on an antibiotic, that is a reason to reconsider the diagnosis rather than escalate the dose.

Drug-induced acneiform eruptions deserve a medication review. Systemic corticosteroids, lithium, some anticonvulsants and epidermal growth factor receptor inhibitors are established causes. The eruption is typically monomorphic — all lesions at the same stage — and appears fairly abruptly after the drug is started. Finally, mechanical and occlusive causes matter more in midlife than people expect: chin straps, CPAP mask edges in women newly diagnosed with sleep apnea, phone pressure, and heavy or oil-based hair products migrating onto the jawline all produce a convincing jawline acne pattern.

When PCOS or another androgen excess disorder should be considered

Most perimenopausal acne needs no endocrine workup. Testing is warranted when acne travels with other signs of androgen excess, because those combinations point to a condition that has its own health implications beyond the skin.

The specific triggers for evaluation are: new coarse, dark, terminal hair growth on the chin, upper lip, chest, abdomen or inner thighs; scalp hair thinning in a male pattern at the crown or widening part; cycles that became irregular or stopped earlier or more abruptly than the menopause transition alone would explain; acne that appeared suddenly and became severe over a matter of weeks; or acne accompanied by voice deepening, clitoral enlargement or rapid muscle bulk change, which raises concern for a rare androgen-producing tumor and warrants prompt evaluation.

Polycystic ovary syndrome does not disappear at 45. Women who had irregular cycles, acne and unwanted hair growth in their twenties often carry the same metabolic phenotype into midlife, where it overlaps confusingly with perimenopause — both produce irregular bleeding, both can produce acne. The distinction matters because PCOS carries associated insulin resistance, type 2 diabetes risk and cardiometabolic risk that deserve separate management, and because a PCOS diagnosis changes how a clinician weighs metabolic screening alongside skin treatment.

When testing is done, it usually includes total and free testosterone, DHEAS as a marker of adrenal androgen output, and, depending on the picture, 17-hydroxyprogesterone to look for non-classic congenital adrenal hyperplasia, prolactin, and thyroid function. Thyroid disease is common in midlife women and, as the American Thyroid Association describes, hypothyroidism produces dry skin, hair changes and fatigue that can muddy the picture even though it does not itself cause acne. Timing of hormone draws is easier in the follicular phase if cycles are still occurring; once cycles are irregular, timing matters less and the clinical picture carries more weight than any single number.

First-line treatment: topical retinoids, and how to actually tolerate them

Topical retinoids are the backbone of acne treatment at every severity level in the American Academy of Dermatology's acne guidelines, and they are the single most important agent for midlife acne specifically. The familiar options are tretinoin, adapalene and tazarotene; trifarotene is a newer addition to the class that came after those guidelines were published. Retinoids normalize how follicular cells shed and stick, which addresses the lesion before it becomes inflammatory, and they have the secondary benefit of improving fine lines and post-inflammatory pigmentation on the same skin you are treating.

They also cause a predictable early phase of dryness, flaking, stinging and a temporary increase in visible lesions, and this is where most midlife regimens die. Adapalene is available over the counter in the United States and is generally the least irritating of the group; tretinoin and tazarotene are prescription and progressively more potent and more irritating. On thinner, drier perimenopausal skin, the sensible starting pattern is a pea-sized amount for the entire face, applied at night two or three nights per week to completely dry skin, increasing frequency only once the skin tolerates it without visible flaking.

Two techniques make the difference. First, apply the retinoid to dry skin — waiting a while after washing rather than applying to damp skin markedly reduces stinging. Second, use a plain moisturizer over it, or under it, from the first night rather than waiting for irritation to appear. There is no requirement to suffer for it to work.

The timeline needs saying plainly: acne treatment is judged over weeks to months, not days. Skin frequently looks worse before it looks better as deeper lesions surface. Abandoning a retinoid in the first weeks and starting something new is the most common reason women conclude that 'nothing works.' Retinoids are also contraindicated in pregnancy, which remains relevant in perimenopause — pregnancy is less likely but not impossible until cycles have been absent for the full twelve months that define menopause.

Benzoyl peroxide and topical antibiotics: the combination rule

Benzoyl peroxide kills Cutibacterium acnes and, importantly, does so without generating bacterial resistance. That property gives it a role beyond its own effect: dermatology guidelines recommend pairing it with any topical or oral antibiotic used for acne, specifically to limit the emergence of resistant organisms. It treats inflammatory lesions and is available without a prescription.

Concentration is not where the benefit lives. Lower-strength formulations are generally as useful for acne as higher ones and are considerably less irritating, which matters on midlife skin. A wash-off cleanser formulation is often better tolerated than a leave-on cream for women who cannot handle both a retinoid and a leave-on benzoyl peroxide on the same face. It bleaches fabric — towels, pillowcases, dark clothing — reliably and permanently, so white linens are a practical accommodation rather than a suggestion.

Topical antibiotics — clindamycin, and erythromycin, though resistance has substantially eroded erythromycin's usefulness — should not be used as monotherapy. The guideline position is unambiguous on this point: used alone, topical antibiotics select for resistance and lose effect. They are used in fixed combination products with benzoyl peroxide, or alongside a retinoid, and for limited periods.

Other topical options fill specific niches. Azelaic acid treats inflammatory lesions and helps post-inflammatory hyperpigmentation, which makes it a reasonable choice for women whose main complaint is the dark marks left behind, and it is generally well tolerated. Salicylic acid has modest comedolytic effect and is widely available. Dapsone gel is another topical option used for adult women with inflammatory lesions. Clascoterone is a topical androgen receptor blocker — a newer agent that arrived after the American Academy of Dermatology guidelines cited here and so is not covered by them, but its mechanism targets the hormonal driver locally rather than systemically, which is of obvious interest to women who cannot or prefer not to take a systemic hormonal drug. It is worth asking a clinician about rather than assuming it is a guideline-backed first step.

Oral antibiotics: useful, time-limited, never alone

For moderate to severe inflammatory acne, oral antibiotics — most often doxycycline or minocycline from the tetracycline class — are part of guideline-supported care. They work through both antibacterial and anti-inflammatory effects. Two constraints define how they should be used.

The first constraint is combination. An oral antibiotic should be prescribed alongside a topical retinoid and benzoyl peroxide, not as a standalone. The retinoid is what maintains the result after the antibiotic stops; without it, acne reliably returns when the course ends, which is how women end up on repeat antibiotic courses for years.

The second is duration. Guidelines direct that oral antibiotic courses be limited rather than open-ended, with reassessment at a defined point and a plan to transition to topical maintenance. Prolonged courses drive antibiotic resistance, disturb the gut and vaginal microbiome, and in midlife women can contribute to recurrent vulvovaginal candidiasis at a time when vaginal tissue is already changing. Doxycycline specifically causes photosensitivity and can cause esophageal irritation if taken lying down or without water. Minocycline carries rarer but more serious risks including drug-induced lupus, hypersensitivity syndrome and blue-grey skin pigmentation with long use.

If acne relapses every time an antibiotic course ends, that is the signal to move to hormonal therapy or isotretinoin rather than to prescribe a fourth course. Repeated antibiotic cycling is the most common pattern of inadequate treatment in adult women, and it delays the treatment that would actually hold.

Hormonal treatment: combined oral contraceptives and spironolactone

Hormonal therapy is where adult female acne treatment diverges most from teenage treatment, and it is explicitly supported in dermatology guidelines for women with inflammatory acne, particularly the jawline-distributed, premenstrually flaring pattern described above.

Combined oral contraceptives work by suppressing ovarian androgen production and by raising sex hormone binding globulin, which lowers free testosterone. Several combined pills — including norgestimate-containing, norethindrone acetate-containing and drospirenone-containing formulations — carry an FDA indication for acne, which is unusual and reflects the evidence base behind them. In perimenopause they have a dual benefit, since they also stabilize erratic bleeding and can blunt vasomotor symptoms while contraception is still needed. Eligibility narrows with age, though: combined pills are generally avoided in women over 35 who smoke, and in anyone with migraine with aura, uncontrolled hypertension, prior venous thromboembolism, certain clotting disorders, or a history of estrogen-sensitive breast cancer.

For women who cannot take estrogen, progestin-only options exist for contraception — the FDA label for the drospirenone 4 mg-only pill covers a 24-day active, 4-day inactive regimen designed to work without estrogen, and the clinical literature on that formulation describes it as an option for women with contraindications to estrogen. It is approved for contraception, not for acne, and should not be chosen on the assumption that it will treat skin.

Spironolactone is the other main hormonal route. It is an aldosterone antagonist that also blocks the androgen receptor and reduces androgen production, and dermatologists use it off-label for adult female acne — it does not carry an FDA acne indication, but it has an established place in practice and is discussed in acne guidelines as an option for women. It suits exactly the population reading this page: adult women with lower-face inflammatory acne who do not want or cannot take estrogen. Common effects include increased urination, breast tenderness, and menstrual irregularity while cycles persist. Potassium is a theoretical concern; monitoring decisions depend on age, kidney function and other medications, particularly ACE inhibitors, angiotensin receptor blockers and potassium supplements, so it is a conversation to have specifically rather than assume. Because of the risk of feminization of a male fetus, pregnancy prevention is discussed when pregnancy remains possible.

Isotretinoin: who it is genuinely for

Isotretinoin is reserved in dermatology guidelines for severe nodular acne, and for acne that is scarring, causing significant psychosocial distress, or failing to respond to adequate courses of the treatments above. It acts on all the main drivers of acne at once, including a marked reduction in sebaceous gland activity, and it is the only acne treatment capable of producing durable remission after the course ends.

In midlife women there are specific considerations. Isotretinoin is severely drying — lips, eyes, nasal mucosa, and the skin generally — and that lands harder on skin and mucous membranes already affected by falling estrogen. Women who also have genitourinary symptoms of menopause or dry eye should raise those before starting, because both can worsen. Laboratory monitoring of liver enzymes and lipids is standard, and lipids in particular deserve attention in a decade when cardiovascular risk is already being reassessed.

Isotretinoin is a potent teratogen. In the United States, prescribing runs through the iPLEDGE risk management program, which imposes pregnancy testing and contraception requirements on anyone who can become pregnant. Perimenopausal women are frequently surprised by this and sometimes assume it will not apply to them; it applies until pregnancy is no longer possible, and the program's criteria — not a patient's assumption about her fertility — determine the requirements.

The decision to use isotretinoin belongs to a dermatologist who has examined the skin. What is worth knowing before that appointment is that persistent nodular acne with scarring does not need to be endured through years of antibiotic cycling first; guidelines allow escalation when the disease is scarring or resistant, not only after every other option has been exhausted.

What menopausal hormone therapy does and does not do for skin

Systemic estrogen therapy is prescribed in menopause for defined indications. The 2022 position statement of The North American Menopause Society frames hormone therapy around vasomotor symptoms, genitourinary syndrome of menopause and prevention of bone loss, with the risk-benefit balance depending heavily on age and time since menopause. Acne is not among the indications, and starting hormone therapy in order to treat skin is not a supported reason to take it.

That said, women already on or considering hormone therapy reasonably ask how it interacts with acne. Because estrogen opposes androgen effects at the skin and raises sex hormone binding globulin, systemic estrogen is not typically an acne aggravator. The progestogen component is the part that varies: progestogens differ in their androgenic character, and some women notice skin changes that track with which progestogen they are taking or with a change in formulation. If acne appeared or clearly worsened in the weeks after a hormone therapy regimen was started or changed, that timing is worth reporting, because a different progestogen or route may be an option within the same treatment plan.

Testosterone deserves a separate warning. Testosterone preparations marketed to midlife women for libido, energy or body composition — including compounded creams and pellets — can cause or dramatically worsen acne, along with unwanted hair growth and scalp hair loss, and pellets in particular cannot be dose-adjusted once implanted. If new acne began after starting any testosterone product, that is the first thing to raise, not the last.

The overall framing that helps: treat the menopause symptoms you have with the treatments indicated for them, and treat acne with acne treatments. The two conversations can happen at the same visit but they are not the same conversation.

Skincare that helps versus skincare that makes it worse

The instinct with breakouts is to strip the skin. In midlife that instinct is actively counterproductive, because a damaged barrier produces redness, stinging and peeling that make prescription treatment intolerable — and the prescription treatment is what actually clears the acne.

The things to stop: physical scrubs, cleansing brushes and any gritty exfoliant, which cause micro-trauma and inflame existing lesions without reducing new ones; alcohol-based toners and astringents; washing more than twice a day; using multiple actives simultaneously from day one; picking or squeezing, which is the most reliable way to convert a lesion that would have healed cleanly into a lasting mark or a permanent scar; and deliberate sun exposure or tanning to 'dry it out,' which darkens existing post-inflammatory pigmentation and does nothing to the acne. Toothpaste, undiluted essential oils and DIY high-strength peels belong on the same list.

The things to do: a gentle non-foaming or low-foaming cleanser twice a day; a plain moisturizer, used consistently and generously, labeled non-comedogenic; daily broad-spectrum sunscreen, which is what prevents the brown marks from deepening and which is non-negotiable alongside retinoids and doxycycline; and one active introduced at a time with enough space between additions so that when something irritates, you know what it was.

A few midlife-specific culprits are worth auditing. Hair products applied at the hairline and along the jaw — oils, leave-in conditioners, heavy stylers — migrate downward and produce a convincing jawline acne pattern. Sustained pressure and occlusion from CPAP mask edges, chin straps and phone contact does the same. Heavy full-coverage foundation and long-wear products are not inherently a problem, but if the routine includes silicone-heavy primers layered under a full-coverage base with no thorough removal at night, simplifying is a low-cost experiment.

A realistic sequence and timeline

The order of operations matters more than any single product. For mild to moderate lower-face acne with no signs of androgen excess, the sensible sequence is: start a topical retinoid at low frequency with a moisturizer, add benzoyl peroxide in a wash form once the retinoid is tolerated, and hold that combination steadily for a full assessment period before changing anything. Most people who conclude a regimen failed did not give it enough time.

If that combination is not controlling the disease, the next step depends on the pattern. Moderate to severe inflammatory acne typically prompts an oral antibiotic added to the topicals for a limited course, with the topicals continuing as maintenance afterward. Acne with a clearly hormonal pattern — jawline distribution, premenstrual flares, relapse immediately after every antibiotic course — is where hormonal therapy earns its place, and going there sooner is often better than a third antibiotic round.

Severe nodular acne, acne that is producing scars, or acne that has failed adequate trials of the above is a dermatology referral for isotretinoin consideration. Scarring is the one thing that cannot be undone later, which is why it justifies escalating faster rather than waiting.

Maintenance is the part that gets skipped. Once acne is controlled, the topical retinoid continues — that is what prevents the microcomedones that become the next crop of lesions. Antibiotics stop; retinoids do not. Women who clear on a combination and then stop everything typically relapse, and the relapse is usually blamed on hormones rather than on the discontinued maintenance.

Marks, scars and what to do about them

Two different things are left behind, and they have different prognoses. Post-inflammatory hyperpigmentation is flat brown or grey discoloration where a lesion was; post-inflammatory erythema is flat red or pink discoloration, more common in lighter skin. Both are pigment or vascular changes in intact skin, and both tend to fade on their own over time. Scars are textural — depressed, raised, or with visible loss of tissue — and they do not fade on their own.

Because flat marks resolve and scars do not, the priority order is: stop new inflammation first, protect from sun relentlessly, and only then treat residual discoloration. Sun exposure is a major factor in how long hyperpigmentation persists, which is why daily broad-spectrum sunscreen is functionally part of acne treatment rather than an optional extra. Topical retinoids and azelaic acid both address discoloration while treating acne, which is a reason to favor them in women whose main distress is the marks.

Picking is the mechanism by which a self-limited lesion becomes a permanent one. This is worth stating without moralizing: extraction pressure deepens inflammation and increases the chance of textural scarring. Removing the magnifying mirror from the bathroom is a legitimate intervention.

Procedural treatment for established scarring — resurfacing, microneedling, subcision, fillers — is a dermatology conversation and is generally deferred until the acne itself is controlled, since active inflammation and some procedures do not mix well. There is no urgency to treat a scar; there is urgency to stop making new ones.

How to get evaluated, and what to bring

Primary care, gynecology and dermatology all treat adult acne, and any of them is a reasonable entry point. Dermatology becomes the right door when the acne is nodular, scarring, resistant to treatment already tried, or when isotretinoin is a realistic consideration. Gynecology is often the more efficient door when acne sits alongside irregular bleeding, contraception questions and other menopause symptoms, since combined oral contraceptives and hormonal management fall naturally into that visit. ACOG's patient material on the menopause years is a useful orientation to what else belongs in that conversation.

Bring three things. First, a photograph of your skin on a bad week, since acne rarely cooperates by flaring on appointment day. Second, a written list of every product currently on your face, including hair products, and every treatment tried with how long each was used and why it stopped — 'I tried a retinoid and it didn't work' means something very different from 'I used a retinoid nightly for a few weeks, my skin peeled, and I stopped.' Third, a full medication and supplement list, including inhaled steroids, hormone therapy, testosterone products and anything compounded.

Ask about the plan rather than the product. The useful questions are how long to give a regimen before judging it, what the maintenance plan is after it works, and what the next step is if it does not — because a treatment plan without a defined reassessment point is how women end up in year three of the same antibiotic.

This site is an information resource and does not prescribe or sell treatment. If the useful next step is a telehealth or in-person clinician who handles menopause-related skin and hormonal care, compare providers on what they actually offer — whether dermatology is available alongside menopause care, whether prescribing includes spironolactone, and whether follow-up is included rather than billed per message.

Questions to ask your clinician

Bring these to your appointment — they turn a vague visit into a decision.

• Does my acne pattern look hormonal to you, and if so, would spironolactone or a combined pill be the better fit for me at my age and with my medical history?
• How long should I stay on this regimen before we decide whether it is working, and what specifically are we looking for at that point?
• Given my age, blood pressure, migraine history and whether I smoke, am I still eligible for a combined oral contraceptive?
• I have new coarse hair on my chin and my part looks wider — should we be testing for androgen excess or PCOS rather than just treating my skin?
• If we use an oral antibiotic, how long is the plan, and what am I switching to for maintenance when it stops?
• Could any of my current medications, supplements, hormone therapy or testosterone products be causing or worsening this?
• Am I developing scars rather than marks, and if so should I be referred to dermatology now rather than trying another course of this?

Frequently asked questions

Why am I getting acne at 47 when I had clear skin as a teenager?

Because the driver is different. Teenage acne follows the rise in androgens at puberty. Perimenopausal acne follows a change in the ratio between androgens and estrogen: estrogen becomes erratic and then declines while androgen production tapers more slowly, so the androgen signal reaching oil glands is relatively stronger. Sex hormone binding globulin also tends to fall, raising the free, biologically active fraction of testosterone. None of this requires an abnormal testosterone level, which is why labs are usually normal in women with clear-cut adult female acne, and why women who never had teenage acne can develop it in their forties.

Do I need hormone testing before treating menopause acne?

Not for typical cases. Adult acne with regular-for-perimenopause cycles, no excess hair growth and no scalp thinning is treated on clinical grounds. Testing becomes appropriate when acne travels with signs of androgen excess: new coarse dark hair on the chin, upper lip, chest or abdomen; male-pattern thinning at the crown; cycles that changed earlier or more abruptly than expected; or acne that appeared suddenly and became severe over weeks. Those situations prompt consideration of PCOS or, rarely, an androgen-producing tumor, and typically include total and free testosterone and DHEAS.

Will hormone therapy for hot flashes clear my skin?

It is not prescribed for that. The 2022 North American Menopause Society position statement frames hormone therapy around vasomotor symptoms, genitourinary syndrome of menopause and bone loss prevention — acne is not an indication, and skin is not a reason to start it. That said, systemic estrogen is not typically an acne aggravator, since it opposes androgen effects at the skin. The progestogen component varies in androgenic character, so if acne began or worsened right after a hormone therapy regimen was started or changed, mention the timing, because a different progestogen or route may be available within the same plan.

How long does it take for acne treatment to work?

Weeks to months, not days, and skin often looks worse first. Topical retinoids in particular cause an early phase of dryness, flaking and an apparent increase in lesions as deeper ones surface. Judging a regimen in its first weeks and abandoning it is the most common reason women conclude nothing works. Give any regimen a defined trial period agreed with your clinician before changing it, and change one thing at a time so you can tell what helped.

Is spironolactone approved for acne?

No. Spironolactone does not carry an FDA indication for acne, but it is widely used off-label by dermatologists for adult female acne and appears in acne guideline discussion as an option for women. It blocks the androgen receptor and reduces androgen production, which targets the mechanism behind jawline-distributed adult acne. It provides no contraception. Common effects include urinary frequency, breast tenderness and menstrual irregularity, and potassium monitoring decisions depend on age, kidney function and other medications such as ACE inhibitors and potassium supplements.

Can I take a birth control pill for acne in my late forties?

Sometimes, and several combined oral contraceptives carry an actual FDA acne indication — norgestimate-, norethindrone acetate- and drospirenone-containing formulations among them. In perimenopause they can simultaneously address erratic bleeding and provide contraception. Eligibility narrows with age, though: combined pills are generally avoided in women over 35 who smoke, and in anyone with migraine with aura, uncontrolled hypertension, prior venous thromboembolism or a history of estrogen-sensitive breast cancer. A progestin-only pill, including the drospirenone-only formulation approved for contraception, is an estrogen-free alternative but is approved for contraception rather than acne.

Should I be washing my face more, or using a stronger cleanser?

No. Over-washing, foaming or alcohol-based cleansers, scrubs and cleansing brushes all damage the skin barrier, and a damaged barrier on thinner midlife skin makes retinoids and benzoyl peroxide intolerable — which removes the treatments that actually work. Twice daily with a gentle cleanser, followed by moisturizer, is the target. Acne is not caused by dirt, and no amount of scrubbing reaches the follicular process driving it.

Are my breakouts actually rosacea?

Possibly, and it is a common mix-up in this age group. Papulopustular rosacea produces inflammatory papules and pustules on the central face but comes with background redness, flushing triggered by heat, alcohol or spicy food, visible small vessels, and no comedones. Benzoyl peroxide and strong retinoids often aggravate it. If your breakouts sit on a persistently red central face and every acne product makes things worse, that is a reason to have the diagnosis reconsidered rather than to escalate acne treatment.

Does diet cause perimenopausal acne?

Diet is not the driver here — the hormonal ratio shift is. There is research interest in glycemic load and in dairy in acne generally, and reducing high-glycemic foods is reasonable for other midlife health reasons, but treating diet as the primary intervention delays the treatments with actual guideline support. One dietary item is worth checking specifically: high-dose supplements, particularly ones sold for hair and nails, are a common unexamined addition to a midlife routine and worth reviewing with a clinician if acne began after starting one.

When should I see a dermatologist instead of managing it myself?

When lesions are deep and nodular, when any scarring has appeared, when over-the-counter adapalene plus benzoyl peroxide has been used correctly for a full trial period without meaningful change, or when acne keeps relapsing the moment an antibiotic course ends. Scarring is the only consequence that cannot be reversed later, so it justifies escalating sooner rather than working through more months of the same approach.

Primary sources

1. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol, 2016. PMID 26897386.
2. Adult female acne: a guide to clinical practice. An Bras Dermatol, 2019. PMID 30726466.
3. American Academy of Dermatology: Adult acne (patient page).
4. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022. PMID 35797481.
5. ACOG: The Menopause Years (patient FAQ).
6. FDA prescribing information, Slynd (drospirenone) 4 mg tablets, 2019.
7. Drospirenone 4 mg-only pill (DOP) in a 24+4 regimen: a new option for oral contraception. Expert Rev Clin Pharmacol, 2020. PMID 32538188.
8. American Thyroid Association: Hypothyroidism.